Why Viking Therapeutics Stock Popped Again Today

1 month ago 15

Rich Smith, The Motley Fool

Tue, Apr 29, 2025, 9:24 AM 3 min read

Viking banal inched higher Monday aft Truist Securities expert Joon Lee lowered his terms target, portion predicting the institution volition payment from signifier 3 objective proceedings quality connected its caller VK2735 measurement nonaccomplishment drug. Today, the shares are advancing by leaps and bounds connected an adjacent much affirmative endorsement from Cantor Fitzgerald's Steven Seedhouse, who says the banal is simply a buy, and predicts the $29 terms volition astir quadruple to deed $104 wrong a year.

Where to put $1,000 close now? Our expert squad conscionable revealed what they judge are the 10 champion stocks to bargain close now. Continue »

Seedhouse doesn't bushed astir the bush: "Our thesis is wholly focused connected pb [injectable] drug, VK2735, a GLP-1/GIP dual agonist entering signifier 3 improvement for wide obesity."

The information that Viking is besides looking to make a VK2735 pill that would destruct needles from the process, and that the institution volition person signifier 2 information connected that pill acceptable successful the 2nd 4th of 2025, is simply a positive for the analyst's bargain thesis. But conscionable getting VK2735 acceptable successful injectable signifier unsocial would beryllium capable of a triumph to much than treble the stock's value, according to this analyst.

Why is Seedhouse truthful excited astir VK2735? Without going excessively acold into the pharmaceutical weeds, the expert argues that its formulation is amended than Eli Lilly's (NYSE: LLY) tirzepatide, successful peculiar by being much potent. According to TheFly.com, Seedhouse thinks it volition outperform Lilly's Zepbound and Mounjaro, and argues that if he's right, "there is simply nary mode the marketplace won't accommodate its emergence to multi-blockbuster status."

All that being said, until the existent objective proceedings information comes out, it's intolerable to accidental for definite that the cause volition beryllium a success, oregon that Viking Therapeutics banal volition spell up arsenic acold and arsenic accelerated arsenic this expert predicts. You pays your wealth and you takes your chances.

My advice, though, is inactive to presumption the banal arsenic speculative and enactment diversified.

Before you bargain banal successful Viking Therapeutics, see this:

The Motley Fool Stock Advisor expert squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and Viking Therapeutics wasn’t 1 of them. The 10 stocks that made the chopped could nutrient monster returns successful the coming years.